Clinical Trials
Page 1 • 12 itemsAccess global clinical trial data, regulatory updates, and competitive intelligence for strategic pharma R&D and investment decisions.
Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Era
Purdue Pharma, the manufacturer of OxyContin, is ceasing operations as part of a $7.4 billion settlement to address its role in the opioid crisis. This landmark agreement aims to resolve thousands of lawsuits and redirect company assets towards addiction treatment and prevention.
CAR-T Cell Therapy Europe: Clinical Trials, Safety & Market Access Insights
Discover the latest insights on CAR-T Cell Therapy in Europe, focusing on clinical trials, safety profiles, and market access for hematologic cancers.
EU Clinical Trials Regulation Impact on Rare Disease Drug Development
This article examines the impact of the EU Clinical Trials Regulation on the development of drugs for rare diseases, focusing on challenges and opportunities for treatments.
EU Clinical Trial Site Selection: Impact of New Qualification Requirements on Timelines
This article examines the implications of new qualification requirements on the timelines for clinical trial site selection in the EU, particularly for oncology drugs.
EU Clinical Trial Ethics Committees: Analysis of Decision Patterns & Timelines
This article analyzes the decision-making patterns and timelines of EU Clinical Trial Ethics Committees, focusing on their impact on drug development in oncology.
European Biomarker-Driven Trials: EMA Regulatory Framework & Success Rates
This article delves into the EMA's regulatory framework for biomarker-driven trials, highlighting success rates and implications for drugs like Keytruda in treating melanoma.
Novel Immunotherapies Advanced Melanoma: EMA Approval & Phase 3 Insights
Discover the groundbreaking EMA-approved immunotherapies for advanced melanoma and insights from recent Phase 3 trials shaping future treatments.
EU Clinical Trials Regulation: Impact on Multinational Trials & Timelines
This article delves into the EU Clinical Trials Regulation, examining its effects on multinational trials and the timelines for drug XYZ in condition ABC treatment.
Clinical Trial Data Sharing in Europe: EMA's New Open Science Mandate
The EMA's new Open Science mandate aims to improve clinical trial data sharing across Europe, fostering transparency and collaboration in drug development.
Phase 1 Trial Evolution: EMA’s New Safety Monitoring Requirements Explained
This article delves into the EMA's updated safety monitoring requirements for Phase 1 trials, focusing on DrugX's role in cancer treatment and patient safety.
Clinical Trial Transparency Europe: Impact of New Results Reporting Rules
This article delves into the implications of new clinical trial results reporting rules in Europe, focusing on drug XYZ's effectiveness for condition ABC.
EU vs US Clinical Trial Protocols: Key Differences in Design & Timelines
This article delves into the critical differences in clinical trial design and timelines between the EU and US, focusing on DrugX for ConditionY.